Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,500 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
最新の財務諸表(Form-10K)によると、Tandem Diabetes Care Incの総資産は$0で、純損失は$0です。
TNDMの主要な財務比率は何ですか?
Tandem Diabetes Care Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Tandem Diabetes Care Incの収益はセグメントまたは地域別にどのように分けられていますか?
Tandem Diabetes Care Inc の最大収益セグメントは Service and Other で、最新の利益発表における収益は 15,670,175 です。地域別に見ると、United States が Tandem Diabetes Care Inc の主要市場であり、収益は 18,966,717 です。
Tandem Diabetes Care Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Tandem Diabetes Care Incの純損失は$0です。